Form 8-K - Current report:
SEC Accession No. 0001785530-21-000025
Filing Date
2021-06-10
Accepted
2021-06-10 07:02:41
Documents
14
Period of Report
2021-06-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K howl-20210610.htm   iXBRL 8-K 36433
2 EX-99.1 a03312021ex991.htm EX-99.1 39586
6 werewolflogohorizontala.jpg GRAPHIC 277881
  Complete submission text file 0001785530-21-000025.txt   608611

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20210610.xsd EX-101.SCH 1946
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20210610_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20210610_pre.xml EX-101.PRE 13621
7 EXTRACTED XBRL INSTANCE DOCUMENT howl-20210610_htm.xml XML 12424
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 211006873
SIC: 2834 Pharmaceutical Preparations